PartnershipUpdated on 12 May 2025
Strategic partnership opportunities for scaling a digital pharma platform
About
NUBINNO CONNECT is a digital platform for pharmaceutical licensing and distribution. With Release 1.0 launching in q4 2025 and over 80 companies pre-registered, we are seeking strategic and venture capital partners to accelerate market entry, customer acquisition, and product expansion. Our vision is to become the leading transaction hub for the pharma industry across Europe and beyond.
Looking for
- Implementation phase
- Others
Organisation
Similar opportunities
Expertise
NUBINNO CONNECT – Pharma B2B platform
Mariusz Wituszynski
Investor Relations at Nubinno Connect
Warsaw, Poland
Project cooperation
Horizon Europe: Digital pharma marketplace for licensing & distribution
Mariusz Wituszynski
Investor Relations at Nubinno Connect
Warsaw, Poland
Project cooperation
- Partner seeks Consortium/Coordinator
- Consortium/Coordinator seeks Partners
- HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
- HORIZON-CL4-2025-03-HUMAN-18: GenAI4EU central Hub (CSA) (AI/Data/Robotics Partnership)
- HORIZON-HLTH-2025-03-TOOL-01-two-stage: Enhancing cell therapies with genomic techniques
- HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
- HORIZON-CL4-2025-04-DATA-03: Software Engineering for AI and generative AI (RIA) (AI/Data/Robotics Partnership)
- HORIZON-CL4-2025-04-DIGITAL-EMERGING-06: Challenge-Driven GenAI4EU Booster (RIA) (AI/Data/Robotics Partnership)
- HORIZON-CL4-2025-03-DATA-13: Fostering Innovative and Compliant Data Ecosystems (IA) (AI, Data and Robotics Partnership)
- Cluster Health (CL1): HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response
- HORIZON-CL4-2025-04-DATA-02: Empowering AI/generative AI along the Cognitive Computing continuum (RIA) (AI/Data/Robotics Partnership)
- HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
- HORIZON-HLTH-2025-01-IND-03: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices
- Cancer Mission: HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers
- HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
- HORIZON-HLTH-2025-01-DISEASE-01: Randomised controlled trials to test safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
- Cluster Health (CL1): HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
- HORIZON-HLTH-2025-03-DISEASE-06-two-stage: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
Robert Lugowski
CEO at CliniNote